Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Monoclonal Antibody Staining Improves Detection of Gastric Bacteria

By LabMedica International staff writers
Posted on 30 Jan 2011
Immunohistochemical staining of endoscopic gastric biopsies with specific antibodies identifies the pathogenic bacteria Helicobacter pylori in upper gastrointestinal diseases. More...


Tissue sections cut from paraffin blocks can be immunochemically stained with polyclonal or specific monoclonal antibodies and examined microscopically to determine the presence or absence of H. pylori.

A retrospective study, conducted by PLUS Diagnostics Laboratories, Union, NJ, USA), used archived material of 300 biopsies that previously had been demonstrated as H. pylori gastritis. The polyclonal antibody immunohistochemical method (NCL-HPp) were compared with slides stained with a Novocastra monoclonal antibody, clone UCL3R (MHP). A monoclonal slide and a polyclonal slide were each prepared with two sections from the same level, that were cut at four micrometer thickness, and immunohistochemical staining was performed on the Bond instrument (Leica Microsystems, Wetzlar, Germany), from whom both the monoclonal and polyclonal antibodies are available.

All study immunohistochemical stained tissue slides were reviewed microscopically by two gastrointestinal pathologists from PLUS Diagnostics with extensive experience in interpretation of immunohistochemical stains and H. pylori assessment. Each set of histological sections were scored, and the results recorded. Results were classified as either positive or negative for H. pylori. The definition of a positive result was the presence of any stained organisms resembling H. pylori bacteria. The definition of negative was the absence of any stained H. pylori-like bacteria.

The sensitivity of the two methods was comparable with 96.2% of the cases identified by the monoclonal antibody method and 98.5% identified by the polyclonal antibody method. The pathologists' evaluations showed that 75.6% of cases displayed high quality organism morphology with the MHP compared with only 34.4% using NCL-HPp, and that 95.8% of cases displayed high quality background staining MHP compared with 87.3% using NCL-HPp.

The authors concluded that the new H. pylori monoclonal ULC3R antibody reagent (MHP) when compared to the polyclonal antibody, NCL-HPp, shows improved quality of organism morphology clarity and reduced nonspecific background staining, whereas the sensitivity of the two methods was comparable. The study was published in January 2011, in LabMedicine.

Related Links:
Leica Microsystems
PLUS Diagnostics




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Electrolyte Analyzer
BKE-B
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.